Posted on 2/4/19
Pfizer's Next 3 Years: What Investors Can Expect
Pfizer (NYSE:PFE) delivered one of its strongest performances in a long time last year. Its stock jumped more than 20% in 2018, handily beating the broader . . .
Posted on 2/4/19
How to Protect Yourself from Medical Malpractice
It’s a no-brainer that healthcare is important and in order to get the best quality care, you will have to be aware of the benefits you . . .
Posted on 2/1/19
Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement
CRANBURY, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that it closed on the final tranche (of four) of its $20.0 . . .
Posted on 2/1/19
Cancer Genetics Announces Closing of Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular . . .
Posted on 1/31/19
Hitachi Chemical To Acquire apceth Biopharma GmbH
Hitachi Chemical Advanced Therapeutics Solutions, LLC announces an agreement by which apceth Biopharma GmbH, a contract manufacturer of cell and gene therapy products
Posted on 1/31/19
Phreesia Named 2019 KLAS Category Leader for Patient Intake Management
Phreesia is pleased to announce it has been named the 2019 Category Leader for Patient Intake Management by the research and insights firm KLAS. In its . . .
Posted on 1/31/19
Alexion and Caelum Biosciences Announce Collaboration
BOSTON & NEW YORK--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is . . .
Posted on 1/31/19
Pfizer: Strong Buy Heading Into 2019
SummaryPfizer reported their fourth-quarter earnings for 2018 yesterday before the market opened, beating analyst expectations narrowly for both revenue and EPS.Poor guidance which fell below analyst . . .
Posted on 1/31/19
3 Big Pharmas Expecting a Softer 2019
Johnson & Johnson (NYSE:JNJ) kicked off this earnings season with a grim outlook for its pharmaceutical business, and it looks like the trouble has spread to . . .
Posted on 1/30/19
Celgene: Long The Deal Spread
SummaryBMY is acquiring CELG in a stock and cash deal currently valued at $98.93 for each share of CELG plus an earn-out worth $9 per share.The . . .
Posted on 1/30/19
Pfizer Q4 Earnings Update: 4 Key Things You Need to Know
You know there was some bad news with a company's quarterly update when the stock drops after the results are announced. That's what happened Tuesday morning . . .
Posted on 1/30/19
Better Buy: Johnson & Johnson vs. Pfizer
Healthcare has given investors great opportunities for a long while, and pharmaceutical specialists in particular have seen plenty of solid gains over time. For Johnson & . . .
Posted on 1/29/19
UroGen Pharma Closes Public Offering of Ordinary Shares
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, . . .
Posted on 1/29/19
Cancer Genetics Announces Proposed Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular . . .
Posted on 1/28/19
Purdue Pharma and Alivio Therapeutics Enter into Partnership
STAMFORD, Conn. & BOSTON--(BUSINESS WIRE)--Purdue Pharma L.P. and Alivio Therapeutics today announced that they have entered into a partnership to advance one of Alivio’s product candidates through . . .
Posted on 1/28/19
BMS Reports Q4: Analysis Of Its Stock And Of Celgene
SummaryBristol-Myers Squibb reported a solid Q4 and pretty good guidance for 2019, but revenue growth is slowing.In that context and given poor new drug development the . . .
Posted on 1/28/19
3 Things You Should Expect in Pfizer's Q4 Earnings Update
Pfizer (NYSE:PFE) gave good news and bad news when it reported third-quarter results in October. The big drugmaker beat Wall Street's earnings estimates, but it missed . . .
Posted on 1/27/19
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 22, 2019 it approved non-statutory stock options to purchase an aggregate of 170,050 shares of its . . .
Posted on 1/25/19
Covered-Call Writing With J&J
SummaryCovered-call writing is one of my favorite strategies to generate monthly income while mitigating downside risk.J&J is a perfect stock to write calls against.After analyzing the . . .
Posted on 1/25/19
Johnson & Johnson: Goodbye Growth
SummaryJohnson & Johnson has seen a real growth slowdown at the end of 2018.Investors should embrace themselves for lower growth in 2019 as well.Slower growth and . . .
Posted on 1/25/19
Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks?
Every January, Johnson & Johnson (NYSE:JNJ) executives share their expectations for the year ahead, and this year investors didn't like what they heard. The company isn't . . .
Posted on 1/25/19
Bristol-Myers Squibb Co (BMY) Q4 2019 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Bristol-Myers Squibb Co (NYSE:BMY)Q4 2018 Earnings Conference CallJan. 24, 2017, 8:30 a.m. ETContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood day, and welcome to . . .
Posted on 1/24/19
Applied DNA Signs Memorandum of Understanding with Sun Chemical Supply Company
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today the signing of a . . .
Posted on 1/24/19
Johnson & Johnson (JNJ) Q4 2018 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Johnson & Johnson (NYSE:JNJ) Q4 2018 Earnings Conference CallJan. 22, 2019 8:30 a.m. ETContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood morning. Welcome to . . .
Posted on 1/24/19
Better Buy: Amgen vs. Johnson & Johnson
Johnson & Johnson (NYSE:JNJ) and Amgen (NASDAQ:AMGN) are two of the most important healthcare companies on the planet. Both companies are massive, highly profitable, and have . . .

